Drug therapy approaches in the treatment of acute severe asthma in hospitalised children

Paediatric Drugs

Volumn 3, Issue 7, 2001, Pages 509-537

  DeNicola, L K ^a   Gayle, M O ^a   Blake, K V ^b  

^a UNIVERSITY OF FLORIDA HEALTH SCIENCE CENTER   (United States)

^b NEMOURS CHILDREN S CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPHYLLINE; ANTIASTHMATIC AGENT; ANTIHISTAMINIC AGENT; ASTEMIZOLE; AZELASTINE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CATECHOLAMINE; CETIRIZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; FUROSEMIDE; HALOTHANE; HELIOX; INHALATION ANESTHETIC AGENT; ISOFLURANE; KETAMINE; KETOTIFEN; LEUKOTRIENE RECEPTOR AFFECTING AGENT; LORATADINE; MAGNESIUM SULFATE; MONTELUKAST; ORCIPRENALINE; PHOSPHODIESTERASE INHIBITOR; SALBUTAMOL; TERBUTALINE; TERFENADINE; UNINDEXED DRUG; ZAFIRLUKAST; ZILEUTON;

ACUTE DISEASE; ASTHMA; CHILD; CHILDHOOD DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG STRUCTURE; HOSPITAL PATIENT; HUMAN; INTUBATION; LUNG DISEASE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESPIRATORY FAILURE; REVIEW; SEDATION;

EID: 0034901893     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128072-200103070-00003     Document Type: Review

References (240)

1. Surveillance for asthma: United States, 1960-1995. CDC Surveillance Summaries
2. International trends in hospital admission rates for asthma
3. The economic burden of asthma in US children: Estimates from the National Medical Expenditure Survey
4. Effects of hydration and physical therapy on tracheal transport velocity
5. Mechanical forces producing pulmonary edema in acute asthma
6. Arterial-blood gas tension in asthma
7. P pulmonale in status asthmaticus
8. Nebulised salbutamol without oxygen in severe acute asthma: How effective and how safe?
9. Arterial oxygen desaturation following salbutamol inhalation in acute asthma
10. Thoracic compression for asthma
11. Emergency treatment of severe bronchospasm
12. External chest compression in acute asthma: A preliminary study
13. Total bronchospasm and lung massage
14. Manual chest compression for total bronchospasm
15. Cardiorespiratory consequences of expiratory chest wall compression during mechanical ventilation and severe hyperinflation
16. Noninvasive positive pressure ventilation
17. Noninvasive positive pressure ventilation in status asthmaticus
18. The effect of adrenocorticotropic hormone (ACTH) and cortisone on the course of bronchial asthma
19. A double-blind trial of corticosteroid therapy in status asthmaticus
20. Double-blind evaluation of methylprednisolone versus placebo for acute asthma episodes
21. A controlled trial of methylprednisolone in the emergency treatment of acute asthma
22. Early intervention with short courses of prednisone to prevent progression of asthma in ambulatory patients incompletely responsive to bronchodilators
23. The mechanism of corticosteroids in treating asthma
24. Mechanisms of glucocorticosteroid action in bronchial asthma
25. Molecular mechanisms of corticosteroid actions
26. Adrenocorticotropic hormone; adrenal steroids and their synthetic analogs; inhibitors of adrenocortical steroid biosynthesis
27. Asthma in children: Emergency management
28. Overview of corticosteroid therapy
29. Myopathy in severe asthma
30. Acute quadriplegia and loss of muscle myosin in patients treated with nondepolarizing neuromuscular blocking agents and corticosteroids: Mechanism at the cellular and molecular levels
31. The pharmacotherapy of acute and chronic asthma
32. Treatment of critical status asthmaticus in children
33. Dosages of corticosteroids in asthma
34. High-dose and low-dose systemic corticosteroids are equally efficient in acute severe asthma
35. Are intravenous corticosteroids required in status asthmaticus?
36. Nebulized dexamethasone versus oral prednisone in the emergency treatment of asthmatic children
37. The use of adrenal substance in the treatment of asthma: 1900
38. Beta-2 agonists
39. Differentiation of receptor systems activated by sympathomimetic amines
40. Molecular mechanisms of anti-asthma therapy
41. Mechanisms of β-adrenergic receptor regulation in lung and its implication for physiological responses
42. Autoradiographic visualization of beta-adrenoreceptor subtype in human lung
43. Beta-adrenergic receptors and their regulation
44. Levalbuterol for asthma
45. Investigation of a cluster of deaths of adolescents from asthma: Evidence implicating inadequate treatment and poor patient adherence with medications
46. The use of beta-agonists and the risk of death and near death from asthma
47. High- versus low-dose, frequently administered, nebulized albuterol in children with severe, acute asthma
48. Nebulize β-adrenergic agents in the treatment of acute pediatric asthma
49. Antiasthmatic therapy in children
50. Beta-adrenergic drugs
51. A comparison of the pharmacology of salbutamol with that of isopro-terenaline, orciprenaline and trimetoquinol
52. Randomized double-blind multicenter study of prostaglandin E1 in patients with adult respiratory distress syndrome
53. Controversies in asthma therapy with theophylline and the beta-2 adrenergic agonists
54. Current status of beta-adrenergic agonists in bronchial asthma
55. β-adrenergic agonists regulate KCa channels in airway smooth muscle by cAMP-dependent and independent mechanisms
56. β-adrenoceptors, cAMP and airway smooth muscle relaxation: Challenges to the dogma
57. 2-adrenergic receptors desensitize in response to in vivo administered beta agonists
58. β-adrenoceptors in human lung bronchus and lymphocytes
59. Clinical pharmacokinetics of β-agonists
60. Pharmacokinetics and absolute bioavailability of salbutamol in healthy adult volunteers
61. Response to frequent low doses of nebulized salbutamol in acute asthma
62. The clinical pharmacology of oral and inhaled salbutamol
63. Systemic absorption of salbutamol following nebuliser delivery in acute asthma
64. Beta adrenergic bronchodilators
65. Clinical use of beta-adrenergic aerosols
66. Comparison of bronchodilator responses and deposition patterns of salbutamol inhaled from a pressurized metered dose inhaler as a dry powder, and as a nebulized solution
67. Pharmacokinetics of terbutaline after oral absorption
68. Adrenergic bronchodilators: Pharmacology and toxicology
69. Absorption of drugs by the lung
70. Self-poisoning with oral salbutamol
71. Comparison of salbutamol given intravenously and by intermittent positive pressure breathing in life-threatening asthma
72. β-adrenergic resistance in normal human airways
73. 2-agonist
74. The bronchodilator responds to inhalation of aerosolized albuterol
75. Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler
76. The management of acute severe asthma
77. Control of asthma by aerosol
78. Aerosol therapy of reversible air flow obstruction
79. Equivalence of continuous flow nebulizer and metered dose inhaler with reservoir bag for treatment of acute airflow obstruction
80. Intermittent versus continuous albuterol administration in acute asthma
81. A prospective randomized study of continuous versus intermittent nebulized albuterol for severe status asthmaticus in children
82. Continuous versus intermittent nebulized terbutaline: Plasma levels and effects
83. Safety of continuous nebulized albuterol for bronchospasm in infants and children
84. Effects of continuous inhalation of albuterol in acute asthma
85. 2 in children with severe asthma treated with continuously nebulized terbutaline
86. Aerosol delivery in intubated mechanically ventilated patients
87. Pressurized aerosol vs. jet aerosol delivery to mechanically ventilated patients: Comparison of dose to the lungs
88. Intravenous Salbutamol in the treatment of status asthmaticus in children
89. Randomised trial of intravenous salbutamol in early management of acute severe asthma in children
90. Intravenous or inhaled salbutamol in severe acute asthma?
91. Dose-response-relationships of intravenously administered terbutaline in children with asthma
92. Salbutamol in the treatment of asthma
93. Comparison of regularly scheduled with as-needed use of albuterol in mild asthma
94. Comparison of R-, S-, and RS-albuterol interaction with human beta 1- and beta 2-adrenergic receptors
95. Improved bronchodilation with levalbuterol compared with racemic albuterol in patients with asthma
96. The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients
97. Pharmacokinetics evaluation in man of terbutaline as separate enantiomers and as the racemate
98. Effect of bronchodilator drugs on peak expiratory flow rates of asthmatic patients: Oral orciprenaline and terbutaline (KWD2019)
99. A comparative clinical trial of different subcutaneous doses of terbutaline and orciprenaline in bronchial asthma
100. Clinical comparison of inhaled terbutaline and orciprenaline in asthmatic patients
101. Comparison of infused and inhaled terbutaline in patients with asthma
102. Continuous intravenous terbutaline infusions for adult patients with status asthmaticus
103. Continuous intravenous terbutaline for pediatric status asthmaticus
104. Terbutaline and muscular symptoms
105. Cardiac arrhythmias during the combined use of intravenous aminophylline and terbutaline in status asthmaticus
106. Diseases of the respiratory system: Bronchial asthma
107. Some remarks on the treatment with caffeine derivatives of asthmatic bronchitis in children
108. Understanding theophylline: Safe and effective use of a complex drug
109. Central nervous system stimulants (continued): The methylxanthines
110. Status asthmaticus
111. Methylxanthine therapy and reversible airway obstruction
112. The pharmacology and therapeutic use of theophylline
113. Theophylline in asthma
114. Overview of effects of theophylline
115. Theophylline
116. Relationships between adenosine, cyclic nucleotides, and xanthines in asthma
117. Enprofylline, a principally new antiasthmatic xanthine
118. Clinical pharmacology of drugs used for asthma
119. Factors influencing theophylline serum protein binding
120. Update on the pharmacodynamics and pharmacokinetics of theophylline
121. Incidence of apparent Michaelis-Menten kinetic behavior of theophylline and its parameters (Vmax and Km) among asthmatic children and adults
122. Pharmacology of the respiratory system
123. Pharmacokinetics of intravenous theophylline
124. Theophylline poisoning. Pharmacological considerations and clinical management
125. Hospital treatment of asthma: Lack of benefit from theophylline given in addition to nebulized albuterol and intravenously administered corticosteroid
126. Emergency treatment of asthma. A comparison of two treatment regimens
127. Aminophylline treatment in severe, acute asthma: A meta-analysis
128. Emergency therapy of asthma: Comparison of the acute effects of parenteral and inhaled sympathomimetics and infused aminophylline
129. Changing trends in the treatment of asthma in a tertiary Canadian pediatric hospital
130. Aminophylline increases the toxicity but not the efficacy of an inhaled beta-adrenergic agonist in the treatment of acute exacerbations of asthma
131. Aminophylline therapy does not improve outcome and increases adverse effects in children hospitalized with acute asthmatic exacerbations
132. Historical review of the use of parasympatholytic agents in the treatment of respiratory disorders
133. Clinical pharmacology and toxicology of ipratropium bromide
134. Effect of ipratropium bromide on airway mucociliary function
135. Anticholinergic, antimuscarinic bronchodilators
136. Cyclic GMP and cyclic AMP in biological regulation: The yin-yang hypothesis
137. Should ipratropium bromide be added to beta-agonists in the treatment of acute severe asthma?
138. Unilateral fixed dilated pupil associated with nebulised ipratropium bromide
139. Inhaled ipratropium bromide and terbutaline in asthmatic children
140. Nebulized anticholinergic and sympathomimetic treatment of asthma and chronic obstructive airway disease in the emergency room
141. Frequent administration by inhalation of salbutamol and ipratropium bromide in the initial management of severe acute asthma in children
142. Should anticholinergics be used in acute severe asthma?
143. Ipratropium bromide added to asthma treatment in the pediatric emergency department
144. Efficacy of frequent nebulized ipratropium bromide added to frequent high-dose albuterol therapy in severe childhood asthma
145. Heliox in the treatment of airflow obstruction: A critical review of the literature
146. Use of helium as a new therapeutic gas
147. Ventilatory and occlusion pressure responses to helium breathing
148. Neuromuscular response to resistive unloading: Helium vs. bronchodilation
149. Oxygenation in status asthmaticus improves during ventilation with helium-oxygen
150. The effect of heliox in acute severe asthma: A randomized controlled trial
151. Deposition in asthmatics of particles inhaled in air or in helium-oxygen
152. Inhaled helium-oxygen revisited: Effect of inhaled helium oxygen during the treatment of status asthmaticus in children
153. 1 in acute asthma patients
154. Evaluation of heliox in children hospitalized with acute severe asthma. A randomized crossover trial
155. Helium-oxygen mixtures in intubated patients with status asthmaticus and respiratory acidosis
156. Fluids and electrolytes
157. Role of calcium ions in transient inward currents and aftercontractions induced by strophanthidin in cardiac Purkinje fibres
158. Magnesium metabolism
159. Calcium efflux from cardiac sarcoplasmic reticulum: Effects of calcium and magnesium
160. Regulation by magnesium of intracellular calcium movement in skinned muscle fibers
161. Intravenous magnesium for acute asthma: Failure to decrease emergency treatment duration or need for hospitalization
162. Effect of magnesium deficiency on mast cells and urinary histamine in rats
163. Magnesium metabolism
164. Blood serum magnesium in bronchial asthma and its treatment by administration of magnesium sulfate
165. Sulfato de madnesia en la crisis de asma
166. Intravenous magnesium sulfate for the treatment of acute asthma in the emergency department
167. Intravenous magnesium therapy for moderate to severe pediatric asthma: Results of a randomized, placebo-controlled trial
168. Intravenous magnesium sulphate in the management of moderate to severe acute asthmatic children nonresponding to conventional therapy
169. High-dose intravenous magnesium sulfate in the management of life-threatening status asthmaticus
170. Bronchodilating effect of intravenous magnesium sulfate in acute severe bronchial asthma
171. Bronchodilating effect of intravenous magnesium sulfate in bronchial asthma
172. Use of magnesium sulfate in asthma in childhood
173. A trial of nebulized magnesium sulfate to reverse bronchospasm in asthmatic patients
174. Aerosolized magnesium sulfate as acute therapy for pediatric asthma
175. Nebulized magnesium sulphate versus nebulized salbutamol in acute bronchial asthma: A clinical trial
176. Safety and efficacy of magnesium sulfate infusions in children with status asthmaticus
177. Acute effect of intravenous magnesium sulfate on airway obstruction of asthmatic patients
178. Effect of magnesium sulfate on cardiovascular hemodynamics
179. Hemodynamic effects of magnesium sulfate on the normal human heart
180. Water, salt, and ions
181. Status asthmaticus. A nine-year experience
182. Use of ketamine in an asthmatic child: A case report
183. Gas chromatography mass spectrometry assay for ketamine and its metabolites in plasma
184. Ketamine block of bronchospasm in experimental canine asthma
185. Ketamine: Its effect on airway resistance in man
186. Elevated plasma norepinephrine concentration during Ketamine anesthesia
187. Ketamine anesthesia
188. Properties of the interaction between ketamine and opiate binding sites in vivo and in vitro
189. Use of ketamine in asthmatic children to treat respiratory failure refractory to conventional therapy
190. Pharmacologic effects of CI-581, a new dissociative anesthetic in man
191. Ketamine anesthesia in minor otologic procedures
192. Cardiovascular and respiratory effects of ketamine in the neonatal lamb
193. Ketamine in the anesthetic management of asthmatic patients
194. Intramuscular ketalar (CI-581) in paediatric anaesthesia
195. Pain management and sedation in the pediatric intensive care unit
196. Neuropsychiatric manifestations of ketamine
197. Side effects of ketamine in pediatric anesthesia
198. Reduction of the psychotomimetic and circulatory side-effects of ketamine by droperidol
199. Ketamine: Its pharmacology and therapeutic uses
200. Ketamine infusion for postoperative analgesia in asthmatics: A comparison with intermittent meperidine
201. Use of ketamine in acute severe asthma
202. Ketamine by continuous infusion in status asthmaticus
203. Randomized, double-blind, placebo-controlled trial of intravenous ketamine in acute asthma
204. Bronchial asthma: Relief of prolonged attack by administration of ether
205. Halothane and enflurane protect against bronchospasm in an asthma dog model
206. The effects of halothane and cyclopropane on total pulmonary resistance in the dog
207. Mechanism for the reduction in pulmonary resistance induced by halothane
208. Maintenance of General Anesthesia
209. Isoflurane: A review
210. Inhalational anaesthetics as an adjunct to ventilator management in severe status asthmaticus
211. Ventricular function in children during halothane anesthesia: An echocardiographic evaluation
212. Respiratory and hemodynamic effects of halothane in status asthmaticus
213. Intracranial hypertension: Therapeutic and anesthetic considerations
214. A comparative interaction of epinephrine with enflurane, isoflurane, and halothane in man
215. Epinephrine-halothane interactions in children
216. Summary of the national halothane study: Possible association between halothane anesthesia and postoperative hepatic necrosis
217. Assessment of the bronchodilator effect of inhaled furosemide compared to salbutamol in asthmatic patients
218. Rapid response to inhaled furosemide in severe acute asthma with hypercapnia
219. Inhaled furosemide is not effective in acute asthma
220. Furosemide and other diuretics in asthma
221. Inhaled diuretics in asthma: The search for the mechanism of action
222. Bronchodilation with a potent and selective leukotriene D4 (LTD4) receptor antagonist (MK-571) in patients with asthma
223. Acute bronchodilation with an intravenously administered leukotriene D4 antagonist, MK-679
224. Comparison of the effects of intravenous and oral montelukast on airway function: A double blind, placebo controlled, three period, crossover study in asthmatic patients
225. Leukotrienes in the blood and urine of children with acute asthma
226. Montelukast added to inhaled beclomethasone in treatment of asthma. Montelukast/Beclomethasone Additivity Group
227. Effects of montelukast (MK-0476); a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroids
228. Effect of oral prednisone on airway inflammatory mediators in atopic asthma
229. Differential effects of fluticasone propionate on allergen-evoked broncho-constriction and increased urinary leukotriene E4 excretion
230. Observations on the effects of aerosolized albuterol in acute asthma
231. Antihistamines in the treatment of asthma
232. Is antihistamine (H1-receptor antagonist) therapy useful in clinical asthma?
233. Allergic rhinobronchitis: The asthma-allergic rhinitis link
234. Phosphodiesterase isozymes: Molecular targets for novel antiasthma agents
235. Phosphodiesterase 4 inhibitors and the treatment of asthma: Where are we now and where do we go from here?